Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Cited by (1,433)

Items 101–200 of 1,433

1. Resistance to proteasome inhibitors and other targeted therapies in myeloma
   Craig Thomas Wallington-Beddoe, Magdalena Sobieraj‐Teague, Bryone Jean Kuss, Stuart Maxwell Pitson · 2018 · British Journal of Haematology
2. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
   Hareth Nahi, Michael Chrobok, Charlotte Gran, Johan Lund, Astrid Gruber, Gösta Gahrton, Per T Ljungman, Arnika Kathleen Wagner, Evren Alici · 2019 · PLoS ONE
3. Glucocorticoids in multiple myeloma: past, present, and future
   Nicholas R. Burwick, Sanjai Sharma · 2018 · Annals of Hematology
4. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
   Torben Plesner, Hendrik‐Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Pierangelo Palumbo, Steen Lisby et al. · 2016 · Blood
5. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
   Tomáš Jelı́nek, Bruno Paiva, Roman Hájek · 2018 · Frontiers in Immunology
6. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
   Thomas G. Martin, Stephen Anthony Strickland, Martha Jane Glenn, Eric Charpentier, Hélène Guillemin, Karl Hsu, Joseph R Mikhael · 2019 · Blood Cancer Journal
7. Multiple myeloma: an overview of management
   Sarah Anne Bird, Kevin D. Boyd · 2019 · Palliative Care and Social Practice
8. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
   Saad Z. Usmani, Hareth Nahi, Torben Plesner, Brendan M. Weiss, Nizar Jacques Bahlis, Andrew Belch, Peter Michael Voorhees, Jacob P. Laubach, Niels W.C.J. van de Donk, Tahamtan Ahmadi et al. · 2020 · The Lancet Haematology
9. Immunotherapy in hematologic malignancies: past, present, and future
   Annie Im, Steven Zivko Pavletic · 2017 · Journal of Hematology & Oncology
10. Management of multiple myeloma in the relapsed/refractory patient
    Pieter Sonneveld · 2017 · Hematology
11. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
    Ľuboš Drgoňa, Carlota Gudiol, Simone Lanini, Bernd Salzberger, Giuseppe Ippolito, Małgorzata Mikulska · 2018 · Clinical Microbiology and Infection
12. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
    Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos, Ralph Wäsch, Mattia D’Agostino, Sophia Scheubeck, Hartmut Goldschmidt, Francesca Gay, Michèle Cavo et al. · 2018 · Leukemia
13. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
    Smith Giri, Alyssa Ann Grimshaw, Susan Bal, Kelly Nicole Godby, Prakash Kharel, Benjamin Djulbegović, Meletios Athanasios Dimopoulos, Thierry T.F. Facon, Saad Z. Usmani, María‐Victoria Mateos et al. · 2020 · JAMA Oncology
14. Plasmablastic lymphoma: current perspectives
    Andrés López, Pau Abrisqueta · 2018 · Blood and Lymphatic Cancer Targets and Therapy
15. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma
    Ajai Chari, Dorothy Romanus, Antonio Pierangelo Palumbo, Marlo A. Blazer, Eileen Farrelly, Aditya Raju, Hui Huang, Paul Gerard Guy Richardson · 2019 · Clinical Lymphoma Myeloma & Leukemia
16. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
    Michèle Cavo, Jesús F. San Miguel, Saad Z. Usmani, Katja Christina Weisel, Meletios Athanasios Dimopoulos, Hervé Avet‐Loiseau, Bruno Paiva, Nizar Jacques Bahlis, Torben Plesner, Vânia Hungria et al. · 2021 · Blood
17. Management of cardiovascular risk in patients with multiple myeloma
    Chris Plummer, Christoph Driessen, Zsolt Roland Szabó, María‐Victoria Mateos · 2019 · Blood Cancer Journal
18. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
    Moritz Binder, Bharat Nayar Nandakumar, S. Vincent Rajkumar, Prashant Kapoor, Francis K. Buadi, David Dingli, Martha Q. Lacy, Morie Abraham Gertz, Suzanne R. Hayman, Nelson Leung et al. · 2021 · Leukemia
19. Biology and management of primary effusion lymphoma
    Shimada, Kazuyuki, Hayakawa, Fumihiko, Kiyoi, Hitoshi · 2018 · Blood
20. Bispecific Antibodies in Multiple Myeloma: Present and Future
    Guido Lancman, Dahniel L. Sastow, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard, Joshua Ryan Richter, Larysa Jessica Sanchez, Ajai Chari · 2021 · Blood Cancer Discovery
21. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
    Estefanía García‐Guerrero, Tea Gogishvili, Sophia Danhof, Martin Schreder, Céline Pallaud, José Antonio Pérez‐Simón, Hermann Einsele, Michael Hudecek · 2017 · Blood
22. Novel immunomodulatory drugs and neo-substrates
    Gao, Shaobing, Wang, Shichao, Song, Yongping · 2020 · Biomarker Research
23. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
    Hervé Avet‐Loiseau, Jesús F. San Miguel, Tineke Casneuf, Shinsuke Iida, Sagar Lonial, Saad Z. Usmani, Andrew G Spencer, Philippe Moreau, Torben Plesner, Katja Christina Weisel et al. · 2021 · Journal of Clinical Oncology
24. Immunomodulatory effects of CD38-targeting antibodies
    Niels W.C.J. van de Donk · 2018 · Immunology Letters
25. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
    Ajay K. Nooka, Nisha S. Joseph, Jonathan L. Kaufman, Leonard T. Heffner, Vikas Anand Gupta, Charise L. Gleason, Lawrence Boise, Sagar Lonial · 2019 · Cancer
26. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
    Nizar Jacques Bahlis, Rachid Baz, Simon J. Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon DJ Gibbs, Sheryl Coppola et al. · 2021 · Journal of Clinical Oncology
27. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow
    Céline Mazzotti, Laure Buisson, Sabrina Mahéo, Aurore Perrot, Marie‐Lorraine Chrétien, Xavier P Leleu, Cyrille Hulin, Salomon Manier, Benjamin Hébraud, Murielle Roussel et al. · 2018 · Blood Advances
28. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
    Ogiya, Daisuke, Liu, Jiye, Ohguchi, Hiroto, Kurata, Keiji, Samur, Mehmet K., Tai, Yu-Tzu, Adamia, Sophia, Ando, Kiyoshi, Hideshima, Teru, Anderson, Kenneth C. · 2020 · Blood
29. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
    Pasquale Luke Fedele, Simon N. Willis, Yang Liao, Michael Sze Yuan Low, Jai Rautela, David Segal, Jianan Gong, Nicholas D. Huntington, Wei Shi, David C.S. Huang et al. · 2018 · Blood
30. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
    Harold Clifford Sullivan, Christian Gerner‐Smidt, Ajay K. Nooka, Connie Maridith Arthur, Louisa Thompson, Amanda Mener, Seema R. Patel, Marianne Elaine McPherson Yee, Ross M. Fasano, Cassandra D. Josephson et al. · 2017 · Blood
31. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Joseph R Mikhael, Paul Gerard Guy Richardson, Saad Z. Usmani, Noopur S Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu et al. · 2019 · Blood
32. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
    Domenico Viola, Ada Donà, Enrico Caserta, Estelle Troadec, Francesca Besi, Tinisha McDonald, Lucy Y. Ghoda, Emine Gulsen Gunes, James F. Sanchez, Jihane Khalife et al. · 2020 · Leukemia
33. Anti CD38 monoclonal antibodies for multiple myeloma treatment
    Alessandro Gozzetti, Sara Ciofini, Martina Simoncelli, Adele Santoni, Paola Pacelli, Donatella Raspadori, Monica Bocchia · 2022 · Human Vaccines & Immunotherapeutics
34. The expansion of targetable biomarkers for CAR T cell therapy
    Michelle H. Townsend, Gajendra Shrestha, Richard A. Robison, Kim Leslie O'Neill · 2018 · Journal of Experimental & Clinical Cancer Research
35. Emerging agents and regimens for multiple myeloma
    Yang Yang, Yi Li, Huiyao Gu, Mengmeng Dong, Zhen Cai · 2020 · Journal of Hematology & Oncology
36. Efficacy of Panobinostat for the Treatment of Multiple Myeloma
    Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2020 · Journal of Oncology
37. Updates on CAR T‐cell therapy in B‐cell malignancies
    Elad Jacoby, Shilpa A. Shahani, Nirali N. Shah · 2019 · Immunological Reviews
38. Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD 38 expression and is related to dismal prognosis
    Marjorie Pick, Vladimir Vainstein, Neta Goldschmidt, David Lavie, Diana Libster, Alexander Gural, Sigal Grisariu, Batia Ronit Avni, Dina Ben Yehuda, Moshe E. Gatt · 2018 · European Journal Of Haematology
39. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits
    Ladan Zand, S. Vincent Rajkumar, Nelson Leung, Sanjeev M. Sethi, Mireille El Ters, Fernando Custodio Fervenza · 2021 · Journal of the American Society of Nephrology
40. Management of acute kidney injury in symptomatic multiple myeloma
    Frank Bridoux, Nelson Leung, Mohamed Belmouaz, Virginie Royal, Pierre Marie Ronco, Samih H. Nasr, Jean Paul Fermand · 2021 · Kidney International
41. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
    Jithma P. Abeykoon, Saurabh Zanwar, Angela A. Dispenzieri et al. · 2018 · Leukemia
42. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David Samuel DiCapua Siegel, Gary John Schiller, Christy Joy Samaras, Michaël Sébag, Jesús G. Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S. Seet, Giampaolo Talamo et al. · 2020 · Leukemia
43. CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
    Luis Gerardo Rodríguez‐Lobato, Maya Ganzetti, Carlos Fernández de Larrea, Michael Hudecek, Hermann Einsele, Sophia Danhof · 2020 · Frontiers in Oncology
44. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
    Giada Bianchi, Yifei Zhang, Raymond L. Comenzo · 2021 · JACC CardioOncology
45. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: <scp>KEYNOTE</scp>‐013
    Ribrag, Vincent, Avigan, David E., Green, Damian J., Wise‐Draper, Trisha, Posada, Juan G., Vij, Ravi, Zhu, Ying, Farooqui, Mohammed Z. H., Marinello, Patricia, Siegel, David S. · 2019 · British Journal of Haematology
46. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
    Marc Steffen Raab, Monika Martha Engelhardt, Antje Blank, Hartmut Goldschmidt, Hermine Agis, Igor Wolfgang Blau, Hermann Einsele, Barbara Ferstl, Natalie Schub, Christoph Röllig et al. · 2020 · The Lancet Haematology
47. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
    Frank M. Cichocki, Ryan Bjordahl, Jodie P. Goodridge, Sajid Mahmood, Svetlana Gaidarova, Ramzey Abujarour, Zachary Davis, Aimee Marie Merino, Katie Tuininga, Hongbo Wang et al. · 2022 · Nature Communications
48. Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
    Yi Zhu, Jiaqi Liu, Joun Park, Priyamvada Rai, Rong Grace Zhai · 2019 · Pharmacology & Therapeutics
49. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
    S. Vincent Rajkumar, Jean Luc Harousseau · 2016 · Blood
50. How I treat myeloma with new agents
    Philippe Moreau · 2017 · Blood
51. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
    Hartmut Goldschmidt, John Ashcroft, Zsolt Roland Szabó, Laurent Garderet · 2018 · Annals of Hematology
52. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
    Bachisio Ziccheddu, Giulia Biancon, Filippo Bagnoli, Chiara De Philippis, Francesco Maura, Even Holth Rustad, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi et al. · 2020 · Blood Advances
53. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Jonas Paludo, Joseph R Mikhael, Betsy R LaPlant, Alese E. Halvorson, Shaji Kunnathu Kumar, Morie Abraham Gertz, Suzanne R. Hayman, Francis K. Buadi, Angela A. Dispenzieri, John Anthony Lust et al. · 2017 · Blood
54. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
    Tomáš Jelı́nek, Renata Bezděková, David Žihala, Tereza Ševčíková, Anjana Anilkumar Sithara, Lenka Pospíšilová, Sabina Ševčı́ková, Petra Polackova, Martin Štork, Zdeňka Knechtová et al. · 2022 · Journal of Clinical Oncology
55. Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
    Enrico Caserta, Junie Chea, Megan Minnix, Erasmus Kofi Poku, Domenico Viola, Steven L. Vonderfecht, Paul J. Yazaki, Desiree M. Crow, Jihane Khalife, James F. Sanchez et al. · 2018 · Blood
56. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma
    Junling Zhuang, Fazal Shirazi, Ramesh Singh, Isere Kuiatse, Hua Wang, Hans Chulhee Lee, Zuzana Berkova, Allison Berger, Marc L. Hyer, Nibedita Chattopadhyay et al. · 2019 · Blood
57. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
    Shih‐Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Kenneth Wen, Tengteng Yu, Phillip A. Hsieh, Nikhil C. Munshi, Joachim Wahl, Katja Matthes et al. · 2020 · Blood Advances
58. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
    Alberto L. Horenstein, Cristiano Bracci, Fabio Morandi, Fabio Malavasi · 2019 · Frontiers in Immunology
59. Second primary malignancies in multiple myeloma: A review
    Christina Poh, Theresa H.M. Keegan, Aaron Seth Rosenberg · 2020 · Blood Reviews
60. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis
    Joseph C. Del Paggio, Ian F. Tannock · 2019 · The Lancet Oncology
61. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
    Philippe Moreau, Meletios Athanasios Dimopoulos, Kwee Yong, Joseph R Mikhael, Marie‐Laure Risse, Gaëlle Asset, Thomas G Martin · 2019 · Future Oncology
62. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
    Estefanía García‐Guerrero, Ralph Götz, Sören Doose, Markus Sauer, Alfonso Rodríguez‐Gil, Thomas Nerreter, Klaus Martin Kortüm, José Antonio Pérez‐Simón, Hermann Einsele, Michael Hudecek et al. · 2020 · Leukemia
63. Actors on the Scene: Immune Cells in the Myeloma Niche
    Patrizia Leone, Antonio Giovanni Solimando, Eleonora Malerba, Rossella Fasano, Alessio Buonavoglia, Fabrizio Pappagallo, Vallì De Re, Antonella Argentiero, Nicola Silvestris, Angelo Vacca et al. · 2020 · Frontiers in Oncology
64. Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design
    Paul Gerard Guy Richardson, Michel Attal, Frank Campana, Solenn Le-Guennec, Ai‐Min Hui, Marie‐Laure Risse, Kathryn P. Corzo, Kenneth Carl Anderson · 2017 · Future Oncology
65. New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
    Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaría Santamaría, José A. García‐Sanz, Leonor Kremer · 2017 · Frontiers in Immunology
66. Daratumumab for the Treatment of Multiple Myeloma
    Torben Plesner, Jakub Krejcik · 2018 · Frontiers in Immunology
67. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
    Irene M. Ghobrial, Chia‐Jen Liu, Oksana Zavidij, Abdel Kareem Azab, Rachid Baz, Jacob P. Laubach, Yuji Mishima, Philippe A. Armand, Nikhil C. Munshi, Frank G. Basile et al. · 2019 · American Journal of Hematology
68. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
    Philippe Moreau, Elena Zamagni, María‐Victoria Mateos · 2019 · Blood Cancer Journal
69. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
    Jiro Kikuchi, Mitsuo Hori, Hidekatsu Iha, Noriko Toyama‐Sorimachi, Shotaro Hagiwara, Yoshiaki Kuroda, Daisuke Koyama, Tohru Izumi, Hiroshi Yasui, Atsushi Suzuki et al. · 2019 · Leukemia
70. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
    Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li et al. · 2017 · Journal of Hematology & Oncology
71. How I treat first relapse of myeloma
    Jean Luc Harousseau, Michel Attal · 2017 · Blood
72. Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
    Eva Vanessa Schrezenmeier, David R.W. Jayne, Thomas Dörner · 2018 · Journal of the American Society of Nephrology
73. Immunotherapy in myeloma: how far have we come?
    Laurens E. Franssen, Tuna Mutis, Henk M. Lokhorst, Niels W.C.J. van de Donk · 2019 · Therapeutic Advances in Hematology
74. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
    Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek et al. · 2021 · Journal of Clinical Oncology
75. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
    Eunju Shin, Seong Ho Bak, Taeho Park, Jin-Woo Kim, Suk Ran Yoon, Haiyoung Jung, Ji‐Yoon Noh · 2023 · Frontiers in Immunology
76. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
    Laurent Garderet, Frédérique Kuhnowski, Benoit Berge, Murielle Roussel, Martine Escoffre‐Barbe, Ingrid Lafon, Thierry T.F. Facon, Xavier P Leleu, Lionel Karlin, Aurore Perrot et al. · 2018 · Blood
77. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
    Guido Lancman, Suzanne A. Arinsburg, Jeffrey S. Jhang, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Joshua Ryan Richter, Ajai Chari · 2018 · Frontiers in Immunology
78. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
    Habte Aragaw Yimer, Jason M. Melear, Edward Anthony Faber, William Bensinger, John M. Burke, Mohit Narang, Don Ambrose Stevens, Sriya W. Gunawardena, Yana Lutska, Keqin Qi et al. · 2019 · British Journal of Haematology
79. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
    Ajai Chari, Paula Rodríguez‐Otero, Helen O. McCarthy, Kenshi Suzuki, Vânia Hungria, Anna Maria Sureda, Aurore Perrot, Cyrille Hulin, Hila Magen, Shinsuke Iida et al. · 2020 · British Journal of Haematology
80. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
    Dickran Gano Kazandjian, Ola Landgren · 2016 · Seminars in Oncology
81. A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma
    Sikander Ailawadhi, Kevin R. Kelly, Robert Allen Vescio, Sundar Jagannath, Jeffrey Lee Wolf, Mecide Meric Gharibo, Taimur Sher, Leyla Bojanini, Maurice William Kirby, Asher Alban Chanan-Khan · 2018 · Clinical Lymphoma Myeloma & Leukemia
82. Immune-based therapies in the management of multiple myeloma
    Saurabh Zanwar, Bharat Nayar Nandakumar, Shaji Kunnathu Kumar · 2020 · Blood Cancer Journal
83. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
    Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione · 2021 · Frontiers in Oncology
84. Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
    Carlos Cuesta‐Mateos, Ana Alcaraz‐Serna, Beatriz Somovilla-Crespo, Cecilia Muñoz‐Calleja · 2018 · Frontiers in Immunology
85. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
    Hartmut Goldschmidt, Marc‐Andrea Baertsch, Jana Schlenzka, Natália Becker, Christina Habermehl, Thomas Hielscher, Marc‐Steffen Raab, Jens Hillengaß, Sandra Sauer, Carsten Müller‐Tidow et al. · 2020 · Leukemia
86. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
    Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G., Schwartz, Elena I., Reiman, Anthony et al. · 2022 · Blood Cancer Journal
87. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
    Jayeeta Ghose, Domenico Viola, Cesar A Terrazas, Enrico Caserta, Estelle Troadec, Jihane Khalife, Emine Gulsen Gunes, James F. Sanchez, Tinisha McDonald, Guido Marcucci et al. · 2018 · OncoImmunology
88. Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
    Meera Mohan, Niels Weinhold, Carolina Schinke, Sharmilan Thanedrarajan, Leo Rasche, Jeffrey R. Sawyer, Erming Tian, Frits van Rhee, Maurizio Zangari · 2019 · British Journal of Haematology
89. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
    Cirino Botta, Domenico Ciliberto, Marco Rossi, Nicoletta Staropoli, Maria Cucè, Teresa Galeano, Pierosandro Tagliaferri, Pierfrancesco Tassone · 2017 · Blood Advances
90. Treatment and disease‐related complications in multiple myeloma: Implications for survivorship
    Rajshekhar Chakraborty, Navneet S. Majhail · 2020 · American Journal of Hematology
91. Monoclonal antibody therapy in multiple myeloma
    Cyrille Touzeau, Philippe Moreau, Charles Dumontet · 2017 · Leukemia
92. Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
    Kathleen W. Zhang, Keith E Stockerl-Goldstein, Daniel John Lenihan · 2019 · JACC Basic to Translational Science
93. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
    Maria Gavriatopoulou, Efstathios Kastritis, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Μαρία Ρούσσου, Magdalini Migkou, Dimitrios C. Ziogas, Nikolaos Kanellias, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2017 · Blood
94. Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
    Brigitte Pegourié, Lionel Karlin, Lotfi Benboubker, Frédérique Orsini‐Piocelle, Mourad Tiab, Sophie Auger‐Quittet, Philippe Rodon, Bruno Royer, Xavier P Leleu, Benoît Bareau et al. · 2019 · American Journal of Hematology
95. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
    Lorraine N. Davis, Daniel W. Sherbenou · 2021 · Cancers
96. Immunopathogenesis and immunotherapy of multiple myeloma
    Hideto Tamura · 2018 · International Journal of Hematology
97. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
    Hanley Abramson · 2018 · International Journal of Molecular Sciences
98. Bispecific T‐cell engagers for treatment of multiple myeloma
    Gayathri Ravi, Luciano J. Costa · 2022 · American Journal of Hematology
99. Panobinostat and Multiple Myeloma in 2018
    Andrew Jenho Yee, Noopur S Raje · 2018 · The Oncologist
100. Current developments in immunotherapy in the treatment of multiple myeloma
     M. Köhler, Christine Greil, Michael Hudecek, Sagar Lonial, Noopur S Raje, Ralph Wäsch, Monika Martha Engelhardt · 2018 · Cancer